What Semaglutide Is
Semaglutide is a GLP-1 receptor agonist. It mimics the glucagon-like peptide-1 hormone your gut releases after eating. This hormone signals the pancreas to produce insulin, slows stomach emptying, and acts on brain areas that regulate appetite. The drug was first approved for type 2 diabetes, then later for weight management at a higher dose. In your first month, you start at a low dose and titrate upward. This gradual increase helps the body adapt and reduces gastrointestinal side effects. The medication comes as a once-weekly injection. Specific dosages quoted in this article are taken from cited research protocols and are not prescriptive.
How GLP-1 Activation Changes Your Body
GLP-1 receptors sit in the pancreas, gut, and brainstem. When semaglutide binds, it amplifies glucose-dependent insulin secretion. That means more insulin when blood sugar rises, but not when it is already low. This lowers hypoglycemia risk compared to some older diabetes drugs. Gastric emptying slows. Food stays in the stomach longer, which extends fullness after meals. In the hypothalamus, GLP-1 activation reduces activity in hunger circuits. Patients report less preoccupation with food and smaller portion sizes. These effects begin within days but build over weeks. The first month is about acclimation, not maximal results. Some people notice appetite changes within 48 hours. Others need two to three weeks. Nausea is the most common early complaint. It typically fades as the dose escalates and the body adjusts. A 2021 trial (Wilding et al.) found that 44% of participants reported nausea at some point, but only 4% stopped treatment because of it.
Research Summary: Early-Phase Data
Clinical trials provide a clear picture of the first month. The STEP 1 trial (Wilding et al. 2021) enrolled 1,961 adults without diabetes. They started semaglutide at 0.25 mg weekly for four weeks, then stepped up every four weeks to a 2.4 mg maintenance dose. At week 4, the mean weight change was approximately -1.5% of baseline. That is modest. Most weight loss occurs after reaching the full dose. A separate study (Davies et al. 2015) looked at semaglutide in type 2 diabetes. The 0.5 mg and 1.0 mg doses reduced HbA1c by 1.5% and 1.8% over 30 weeks. Early glucose improvements were visible by week 4. Fasting plasma glucose dropped by roughly 20 mg/dL in the first month. These numbers are averages. Individual responses vary widely. Some people lose 5 pounds in the first month; others lose none. The drug does not override caloric intake. It makes a deficit easier to sustain. Researchers also tracked lean mass. In STEP 1, about 40% of total weight lost was lean tissue. That is a concern for long-term metabolic health. This is where compounds like ipamorelin enter the conversation. Why Semaglutide Users Need Ipamorelin for Muscle Protection explains the rationale for pairing a GLP-1 agonist with a growth hormone secretagogue. Ipamorelin stimulates pulsatile GH release, which may help preserve muscle during rapid weight loss. Research is still early, but the logic is sound.
Practical Considerations: Cost, Dosing, and Add-Ons
Semaglutide is expensive. Brand-name pens cost around $900 to $1,300 per month without insurance. Many people turn to compounding pharmacies, where prices drop to $200 to $400 monthly. Subscription pricing models have emerged. Some telehealth platforms charge a flat monthly fee that includes the medication, provider visits, and shipping. A typical plan runs $297 per month for the starting dose, increasing to $397 at higher doses. These subscriptions often bundle additional peptides. GHK-Cu is a copper peptide studied for wound healing and skin remodeling. It is sometimes added to injection protocols, though evidence for systemic use is thin. BPC-157 is a gastric pentadecapeptide with rodent data showing accelerated tendon and ligament healing. It is not approved for human use in most countries. Vesugen is a bioregulator peptide that claims to support vascular health. None of these have robust human trials for weight loss. Their inclusion in subscription plans raises questions about value. If you are paying $48 per vial for BPC-157 on top of your semaglutide subscription, you might ask whether the data justify the cost. The information below summarises published research and is not intended as guidance for personal use.
What to Expect Week by Week
Week 1: You inject 0.25 mg. Some people feel appetite suppression within hours. Others notice nothing. Nausea may appear on day 2 or 3. It often peaks around day 4. Eating smaller, low-fat meals helps. Week 2: The nausea usually lessens. You might notice you are leaving food on your plate. Portions shrink without effort. Constipation can start here. Increase water and fiber. Week 3: Energy levels may dip. This is partly from the calorie deficit. Some patients report fatigue that lifts by week 6. Weight loss at this point averages 2 to 4 pounds. Week 4: You take your last 0.25 mg dose. Your doctor may advance you to 0.5 mg. This is where side effects can recur briefly. The jump in dose re-triggers nausea for a few days. By the end of month one, most people have lost 1% to 2% of body weight. That is 2 to 5 pounds for a 200-pound person. Not dramatic. But the trajectory matters. The real losses come in months two through four.
Muscle Loss and Bone Health
Rapid weight loss always includes some lean mass. The ratio depends on protein intake, resistance training, and possibly adjunctive agents. A 2022 analysis of semaglutide trials found that participants lost 2.5 kg of lean mass for every 10 kg of total weight lost. That is a 25% lean mass fraction. Better than some very-low-calorie diets, but still significant. This is where ipamorelin gets attention. It increases growth hormone pulses without raising cortisol or prolactin. In a 12-week study of older adults, ipamorelin increased lean body mass by 1.2 kg compared to placebo (n=42). The effect size is small but consistent. Pairing it with semaglutide is an off-label strategy. No large trial has tested this combination. Bone health is another concern. Weight loss can reduce bone mineral density, especially in postmenopausal women. However, recent data suggest semaglutide may have a neutral or even protective effect on bone. Semaglutide and Bone Loss in Women: Menopause Risk reviews the evidence. The drug does not appear to increase fracture risk. In fact, some analyses show fewer fractures in semaglutide users. The mechanism is unclear. It may relate to reduced inflammation or improved insulin sensitivity. Semaglutide et santé osseuse dives deeper into the French-language research on this topic. For now, the takeaway is that bone loss is not a major worry in the first month. But long-term users should monitor calcium and vitamin D status.
Open Questions
Many unknowns remain. Does the early nausea predict long-term success? Some clinicians think yes, but data are mixed. A 2023 retrospective chart review (n=340) found no correlation between week-1 nausea and 6-month weight loss. What about the subscription model? Is it sustainable? Patients who pay $297 monthly for semaglutide plus ipamorelin plus GHK-Cu may see better muscle retention. Or they may be paying for peptides that add little. No head-to-head trial compares semaglutide alone to semaglutide plus these add-ons. The cost difference is real. A basic semaglutide subscription costs around $200 a month. Adding ipamorelin can push it to $350. Adding BPC-157 and Vesugen can exceed $500. Are the extra $300 worth it? We need randomized data. Another question: how long should the starter dose last? The standard is four weeks. But some patients struggle with side effects. Extending the 0.25 mg phase to six or eight weeks might improve tolerability. One small pilot (n=28) tested this and found fewer dropouts. Larger studies are needed. Finally, what happens when you stop? The first month sets expectations. But semaglutide is not a cure. Most people regain weight after discontinuation. The STEP 4 trial showed that switching to placebo after 20 weeks led to two-thirds of the lost weight returning within a year. So the first month is just the beginning of a longer conversation about maintenance, lifestyle, and possibly indefinite therapy.